Virtual Symposium and Case Simulation (CME concluded): Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes

In this symposium, faculty will overview the management of hypercholesterolemia to reduce the risk of adverse atherosclerotic cardiovascular disease (ASCVD) events, including how to identify patients with statin intolerance or with residual risk despite maximized statin therapy, as well as current management of elevated cholesterol with statin and non-statin therapies according to the updated guidelines. In addition, the symposium will summarize the evidence on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and emerging cholesterol-lowering therapies. Challenges with access to newer therapies and appropriate resources to address this issue will also be reviewed.

During the activity, case-based, patient simulation technology will be utilized to provide learners with the opportunity to explore different decision paths and get immediate feedback on their treatment decisions, allowing for enhanced competence in the individualization of therapy for patients at-risk for ASCVD.

Learners are also provided online access and a PDF copy of a Rapid Review Pocket Guide: Guidance on Cholesterol Management.

LDL-C Treatment Intensification

Chairperson: Christie M. Ballantyne, MD

Interactive Case Simulation
Identifying Patients at Risk for Residual Risk Despite Statin Therapy

Presenter: Leslie Cho, MD

Non-Statin Therapies for LDL-C

Chairperson: Christie M. Ballantyne, MD

Live Meeting Case Simulation Results Discussion

Panel: All Faculty

Challenges in PCSK9 Inhibitor Access

Chairperson: Christie M. Ballantyne, MD